US Patent Issued to Bristol-Myers Squibb, Janssen Pharmaceutica on Aug. 5 for "Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b[1,7diazacyclotetradecin-5(6H)-one" (Belgian, Swiss, American Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,246, issued on Aug. 5, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.) and Janssen Pharmaceutica NV (Beerse, Belgium).

"Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b[1,7diazacyclotetradecin-5(6H)-one" was invented by Nicolas Cuniere (Princeton, N.J.), Yu Fan (Highland Park, N.J.), Sergei Kolotuchin (Princeton, N.J.), Subha Mukherjee (Princeton, N.J.), Eric M. Simmons (Princeton, N.J.), Amarjit Singh (Princeton, N.J.), Carolyn S. Wei (Princeton, N.J.), Yi Xiao (Princeton, N.J.), Changxia Yuan (Princeto...